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OBJECTIVES This study examined the effect of physiologic pacing on the development of chronic atrial
fibrillation (CAF) in the Canadian Trial Of Physiologic Pacing (CTOPP).
BACKGROUND The role of physiologic pacing to prevent CAF remains unclear. Small randomized studies
have suggested a benefit for patients with sick sinus syndrome. No data from a large
randomized trial are available.
METHODS The CTOPP randomized patients undergoing first pacemaker implant to ventricular-based
or physiologic pacing (AAI or DDD). Patients who were prospectively found to have
persistent atrial fibrillation (AF) lasting greater than or equal to one week were defined as
having CAF. Kaplan-Meier plots for the development of CAF were compared by log-rank
test. The effect of baseline variables on the benefit of physiologic pacing was evaluated by Cox
proportional hazards modeling.
RESULTS Physiologic pacing reduced the development of CAF by 27.1%, from 3.84% per year to 2.8%
per year (p 5 0.016). Three clinical factors predicted the development of CAF: age $74 years
(p 5 0.057), sinoatrial (SA) node disease (p , 0.001) and prior AF (p , 0.001). Subgroup
analysis demonstrated a trend for patients with no history of myocardial infarction or coronary
disease (p 5 0.09) as well as apparently normal left ventricular function (p 5 0.11) to derive
greatest benefit.
CONCLUSIONS Physiologic pacing reduces the annual rate of development of chronic AF in patients
undergoing first pacemaker implant. Age $74 years, SA node disease and prior AF predicted
the development of CAF. Patients with structurally normal hearts appear to derive greatest
benefits. (J Am Coll Cardiol 2001;38:167–72) © 2001 by the American College of
Cardiology
Atrial fibrillation (AF) is the most common sustained
arrhythmia and is associated with significant morbidity,
mortality and substantial costs to the health care system
(1{5). In fact, in the Framingham Heart study, AF was
found to be a risk factor for death independent of other
cardiovascular conditions (4). The role of pacing for the
prevention of AF remains unclear. Specifically, the benefit
of physiologic (atrial pacing or dual chamber pacing) over
ventricular-based pacing on the development of and pro-
gression to chronic AF (CAF) in patients undergoing
pacemaker implant remains unknown. Retrospective trials
have suggested that physiologic pacing is associated with a
reduction in CAF in patients undergoing pacemaker inser-
tion (6–10). Due to the retrospective nature of these trials,
it remains likely that selection bias contributed significantly
to the outcomes measured. Two small, randomized trials
comparing physiologic pacing with ventricular-based pacing
have suggested a reduction in the rate of development of
CAF (11–13). This benefit appeared to be seen predomi-
nantly in patients undergoing pacing for sick sinus syn-
drome.
The Canadian Trial Of Physiologic Pacing (CTOPP)
(14) randomized 2,568 patients undergoing first pacemaker
implant regardless of indication to physiologic versus
ventricular-based pacing. It was hypothesized that physio-
logic pacing would reduce the incidence of AF in these
patients and, consequently, statistically reduce the incidence
of stroke or cardiovascular death. In CTOPP, physiologic
pacing was found to reduce the annual rate of AF by 18%.
However, this modest reduction in the rate of AF did not
translate into a reduction in the composite primary end
point of stroke or cardiovascular death. The short follow-up
of three years may have reduced the ability to demonstrate
an effect on stroke and cardiovascular death as the reduction
in AF was seen only after two years. Alternatively, the
treatment effect of physiologic pacing on total AF
(paroxysmal AF and CAF) was of insufficient magnitude to
reduce the incidence of stroke or cardiovascular death.
Therefore, to further delineate the treatment effect of
physiologic pacing on total AF burden, analysis of the
prospectively determined end point of CAF was performed.
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We hypothesized that the treatment effect of physiologic
pacing would be greater using an end point of CAF. This
would provide further evidence for a significant treatment
effect of physiologic pacing. We also sought to determine
clinical risk factors that predict greatest benefit from phys-
iologic pacing for the prevention of CAF.
METHODS
Thirty-two Canadian centers participated in the CTOPP
trial, which has been reported elsewhere (14). Patients were
eligible if the following inclusion criteria were met: 1) first
pacemaker implantation, 2) absence of CAF, 3) age .18
years old. Patients were excluded if the pacemaker indica-
tion was related to atrioventricular (AV) node ablation or if
the patients were not expected to survive two years. Im-
planting centers were allowed to choose one of a number of
randomization ratios resulting in an uneven randomization
(57:43 ventricular:physiologic).
After giving informed consent, patients were randomized
no more than 48 h before the scheduled pacemaker implant.
Patients randomized to physiologic pacing could receive a
dual-chamber device or an atrial pacemaker if an intraop-
erative atrial pacing test demonstrated 1:1 AV conduction
up to an atrial rate of 130 beats/min. Patients in both
treatment arms were required to receive a rate responsive
pacemaker if chronotropic incompetence was demonstrated
or if permanent third-degree AV block was the indication
and patients were randomized to the ventricular arm.
Baseline clinical characteristics have been published and
were well balanced between the groups (14). Briefly, the
indication for pacing was AV nodal disease alone in 52% of
patients and sinoatrial (SA) disease alone in 35% of patients.
Demographics for the entire study population are tabulated
in Table 1.
The primary outcome for the trial was the composite end
point of stroke or cardiovascular death. The development of
AF after randomization was also considered an important
outcome. An occurrence of AF was defined as any docu-
mented episode of AF lasting greater than 15 min. Docu-
mentation of AF required electrocardiogram (ECG) or
rhythm strip evidence. All patients who were found to have
had an episode of AF were required to return for subsequent
rhythm recording (ECG or rhythm strip) at one week.
Patients who were found to have persistent AF lasting
greater or equal to one week were defined as having CAF.
The cumulative risk of developing CAF over time from
randomization was estimated using the Kaplan-Meier (15)
approach and compared between treatments with a Mantel-
Haenszel test (16) stratified by center. The stratification was
prespecified and based on the fact that the fraction of
patients randomized to conventional pacing was allowed to
vary from center to center. Cox’s proportional hazard model
(17) was used in the analysis. Although we have quoted the
annualized event rates (number of events/patient years at
risk) as useful summary statistics, treatment effects have
been expressed as hazard ratios and relative risk reductions
(i.e., 1-hazard ratio) with their associated confidence inter-
vals (CI) and p values. The Cox model was also used both
to explore the way patient factors influenced the subsequent
risk of CAF and to look for potential “subgroup effects.”
Several clinical factors were included in the model: age
$74 years, (the median for the group), history of docu-
mented myocardial infarction (MI) or documented coronary
artery disease (CAD) without prior MI, documented prior
AF (duration . 30 s) in the prior six months, history of
hypertension, history of diabetes mellitus, evidence of doc-
umented sinus node disease or left ventricular (LV) function
assessed as either normal or abnormal. Patients with docu-
mented assessment of LV function (LV angiogram of
echocardiography) within the prior two years had LV
function determined by this assessment. Left ventricular
Abbreviations and Acronyms
AF 5 atrial fibrillation
AV 5 atrioventricular
CAD 5 coronary artery disease
CAF 5 chronic atrial fibrillation
CI 5 confidence interval
CTOPP 5 Canadian Trial Of Physiologic Pacing
ECG 5 electrocardiogram
LV 5 left ventricle or left ventricular
MI 5 myocardial infarction
QOL 5 quality of life
SA 5 sinoatrial
VVIR 5 ventricular-based rate-responsive pacing
Table 1. Baseline Patient Characteristics
All
Patients
(n 5 2,568)
Mean age 72.7 6 10.3
Male gender 58.8%
NYHA class $2 39.0%
Pacing indication
SA node disease 33.7%
AV node disease 51.6%
Both 8.3%
Other 4.2%
Unknown 2.3%
Medical history
Myocardial infarction 25.1%
Documented CAD 17.5%
Stroke or TIA 9.5%
Prior atrial fibrillation 21.1%
Diabetes mellitus 14.8%
Systemic hypertension 35.2%
Left ventricular function
Clinical assessment—normal* 51.3%
Clinical assessment—abnormal* 11.9%
Objective assessment—normal† 18.6%
Objective assessment—abnormal† 16.1%
*Physician clinical impression of left ventricular systolic function; †left ventricular
systolic function assessed by echocardiography or angiography.
AV 5 atrioventricular; CAD 5 coronary artery disease; NYHA 5 New York
Heart Association; SA 5 sinoatrial; TIA 5 transient ischemic attack.
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function was determined to be abnormal if a wall motion
abnormality or hypertrophy was seen. If LV function had
not been assessed in the prior two years, a presumptive
assessment was made as apparently normal or abnormal
based on clinical assessment.
RESULTS
Two thousand five hundred sixty-eight patients were ran-
domized with a ratio of 57:43 (ventricular:physiologic),
resulting in 1,474 ventricular-based implants and 1,094
physiologic pacing implants. Physiologic pacing reduced the
rate of development of CAF from 3.84% per year to 2.80%
per year, a relative risk reduction of 27.1%, (95% CI: 5.5 to
43.6, p 5 0.016). Figure 1 shows the cumulative risk of
development of CAF over time. The curves separate at
approximately six months and continue to diverge thereaf-
ter.
Of the clinical factors investigated in this study, three
predicted the development of CAF after controlling for
treatment. Age $74 years was associated with an annual
risk of 3.83% versus 2.95% for those ,74 years (p 5 0.057).
The presence of SA node disease was associated with an
annual risk of 5.66% versus 1.86% for those without (p ,
0.001). Prior AF was associated with an annual risk of
9.64% versus 2.04% for those without (p , 0.001) (Table
2). Other clinical factors were not statistically predictive for
the development of CAF.
To determine whether specific subgroups might derive
more or less benefit from physiologic pacing, Cox propor-
tional hazard modeling was performed. For each subgroup,
hazard ratios with 95% CIs are reported in Table 3. Figure
2 illustrates these results graphically, including the associ-
ated CIs and p values. The treatment effect of physiologic
pacing was evenly distributed among all subgroups except
those with a history of MI or coronary disease and those
patients with abnormal LV function who appeared to derive
no benefit. There was a statistical trend for patients free of
previous MI or CAD and patients with apparently normal
LV function to derive greatest benefit from physiologic
pacing. The hazard ratios of treatment effect for those
patients with and without prior MI or CAD are 0.62 (95%
CI: 0.45 to 0.86) and 1.0 (95% CI: 0.64 to 1.55, p 5 0.09).
The hazard ratios of treatment effect for those patients with
normal and abnormal LV function are 0.64 (95% CI: 0.47
to 0.87) and 1.01 (95% CI: 0.63 to 1.62, p 5 0.11). Patients
Figure 1. Cumulative risk of the development of chronic atrial fibrillation over time for the groups receiving ventricular (V) and physiologic (P) pacing.
The curves diverge between 6 and 12 months and continue to diverge over time.
Table 2. Clinical Predictors of Chronic AF
Factor Status
Chronic AF
p Value
for HREvents Rate/yr
Treatment Ventricular 167 3.84
Physiologic 92 2.8 0.016
Age ,74 112 2.95
$74 147 3.83 0.057
SA node disease No 82 1.86
Yes 171 5.66 , 0.001
Prior AF No 128 2.04
Yes 131 9.64 , 0.001
MI/CAD No 175 3.23
Yes 84 3.79 0.425
Hypertension No 158 3.16
Yes 101 3.85 0.261
Diabetes No 223 3.37
Yes 36 3.50 0.715
LV function Normal 188 3.30
Abnormal 71 3.65 0.473
AF 5 atrial fibrillation; HR 5 hazard ratio; LV 5 left ventricular; MI/CAD 5
myocardial infarction/coronary artery disease; SA 5 sinoatrial.
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with SA node disease did not appear to derive greater
benefit from physiologic pacing (p 5 0.65).
DISCUSSION
The major finding of this study was that physiologic pacing
is associated with a reduction in the rate of development of
CAF in patients undergoing first pacemaker implant. The
current analysis demonstrated a 27% relative risk reduction,
from 3.84% per year to 2.80% per year, in the annual rate of
development of CAF over a mean follow-up period of three
years. This supports the primary analysis of the CTOPP,
which found a reduction in the annual incidence of any
episode of AF from 6.6% per year with ventricular-based
pacing to 5.3% per year with physiologic pacing, a 18%
relative risk reduction over the same period (14). Taken
together, these analyses provide strong evidence that phys-
iologic pacing reduces the burden of AF in a large cohort of
patients undergoing pacemaker implantation. It remains to
be seen whether this will translate into a reduction in stroke
or cardiovascular death with longer follow-up. Given the
magnitude of reduction of CAF with physiologic pacing,
this remains an entirely plausible hypothesis.
Few studies have prospectively studied the effect of
physiologic pacing on the development of paroxysmal or
CAF. Andersen et al. (11) randomized 225 patients exclu-
sively with sick sinus syndrome to receive atrial physiologic
rate-responsive pacing (AAIR) or ventricular-based rate-
responsive pacing (VVIR). The initial analysis at a
follow-up of 3.3 years failed to demonstrate a reduction in
the incidence of AF. However, after a mean of 5.5 years, a
reduction in the incidence of total AF and CAF was
demonstrated (12). A second trial randomized 210 patients,
110 with sick sinus syndrome and 100 with AV block to
physiologic pacing or VVIR (13). Physiologic pacing was
associated with a significant reduction in the incidence of
CAF over a maximum follow-up of five years; however, the
magnitude of the benefit was not reported. The Pacemaker
Selection in the Elderly (PASE) study compared quality of
life (QOL) measurements as well as the rate of development
Table 3. Hazard Ratios and 95% Confidence Intervals for
Subgroup Analysis
Factor
Hazard
Ratio*
Lower
Limit
Upper
Limit p Value†
Age ,74 0.65 0.43 0.97
$74 0.78 0.56 1.09 0.47
MI/CAD No 0.62 0.45 0.86
Yes 1.0 0.64 1.55 0.09
LV function Normal 0.64 0.47 0.87
Abnormal 1.01 0.63 1.62 0.11
SA node disease No 0.66 0.41 1.04
Yes 0.75 0.54 1.03 0.65
Atrial fibrillation No 0.65 0.45 0.95
Yes 0.8 0.56 1.15 0.45
Hypertension No 0.71 0.51 0.99
Yes 0.76 0.50 1.15 0.8
Diabetes No 0.76 0.57 1.0 0.47
Yes 0.57 0.27 1.19
*The hazard ratio gives the treatment effect of physiologic pacing relative to
ventricular pacing in the given subgroup; †the p value is for the test of interaction
between treatment and the risk factor.
LV 5 left ventricular; MI/CAD 5 myocardial infarction/coronary artery disease;
SA 5 sinoatrial.
Figure 2. Distribution of treatment effect of physiologic pacing by subgroup. The hazard ratios (solid circle) and the 95% confidence intervals are plotted
for the treatment effect of physiologic pacing. Associated p values are shown. See text for details. Afib 5 atrial fibrillation; Hypten 5 hypertension; LVF 5
left ventricular function; MICAD 5 myocardial infarction or coronary artery disease; SA 5 sinoatrial.
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of AF in 407 patients. All received a dual chamber pace-
maker but were randomized to dual chamber physiologic or
ventricular pacing modes (18). Physiologic pacing was not
associated with substantial improvement in QOL measure-
ments or a reduction in the incidence of AF. Subgroup
analysis of 175 patients with SSS was performed and
demonstrated trends toward reductions in the secondary
outcomes of death (20% to 12%, p 5 0.09) and AF (28% to
19%, p 5 0.06). As such, prior to CTOPP, the evidence
that physiologic pacing prevents CAF comes exclusively
from three small prospective trials representing approxi-
mately 500 patients with sick sinus syndrome.
The current analysis of 2,568 patients is the largest and
most comprehensive prospective study to investigate the
effect of physiologic pacing on the development of CAF.
The benefit of physiologic pacing did not appear to be
affected by the indication for pacing. Specifically, the group
with sick sinus syndrome did not appear to derive greater
benefit in this analysis or in the parent CTOPP analysis
(14). It is important to note that the study by Andersen et
al. (11,12) utilized exclusively atrial-based pacing, whereas
the majority of physiologic pacing in CTOPP was dual
chamber. The preserved synchronization of right ventricular
or LV contraction with atrial pacing may be an important
factor in the development of AF and subsequent stroke.
Clearly, this hypothesis remains untested but warrants
further study.
The current study also found clinical predictors for the
development of CAF in this group. Not surprisingly, age
$74 years, history of documented sinus node disease and a
history of documented prior AF predicted the development
of AF during follow-up. Previous retrospective (6–10) and
small prospective studies have demonstrated similar findings
in patients undergoing pacemaker implantation (11–13,15).
Subgroup analysis was performed to determine clinical
factors that might predict the most benefit from physiologic
pacing. It appeared that patients with preserved LV func-
tion and patients with no history of MI or CAD derive the
most benefit from physiologic pacing. While the difference
in hazard ratio in these subgroups did not reach statistical
significance, a clear trend was seen. The 95% CIs are very
wide, suggesting a small number of events within these
groups. As these patients continue to be followed and
further events are documented, the significance of these
results will become clearer.
The magnitude of the treatment effect with physiologic
pacing was modest. An absolute reduction of 1% per year
translates into the prevention of CAF in one of every
hundred patients per year undergoing physiologic perma-
nent pacemaker implantation. Ninety-five percent of phys-
iologic pacing in CTOPP was accomplished with dual
chamber implants (13). Based on a significant incremental
cost per implant of dual chamber pacing (estimated to be
approximately $2,000 to $3,000 [U.S.] per implant for
hardware and leads only), widespread use of dual chamber
pacing to prevent the development of CAF appears to be a
costly endeavor. However, given the fact that AF is exceed-
ingly common (1,2) and is associated with substantial health
care costs (3), physiologic pacing may prove to be a
cost-effective therapy despite only modest reductions in AF
burden. Selection of patients without significant coronary
disease or LV dysfunction may further predict a subgroup
that will derive greater and most cost-effective benefit from
physiologic pacing.
Study limitations. Although part of the current analysis
represents subgroup analysis, the end point of CAF was a
prospectively defined secondary end point. Furthermore, the
subgroup analysis was also prospectively planned, and rele-
vant data was prospectively collected. Thus, due to the large
study cohort, the estimation of benefit of physiologic pacing
in preventing CAF and the subgroup analysis is important
and likely valid.
The duration of AF determined to be chronic was brief.
However, the definition was such that patients whose AF
was paroxysmal and self-terminating were eliminated.
Hence, it likely represents a clinically meaningful group. No
attempt was made to document episodes of asymptomatic
AF using loop recorders or pacemaker monitoring func-
tions. There is no reason to believe that the methodology
would document episodes of AF to a greater degree in one
pacing group than in the other. Also, no attempt was made
to classify patients into “persistent” versus “permanent” AF,
as this involved judgements determined by the treating
physician as to ability or desire to perform DC cardiover-
sion.
Decisions about the use of medications were left to the
treating physician. Data with respect to drug use were not
systematically collected in the trial. However, 12% of the
population was taking antiarrhythmic agents for prior AF at
baseline equally distributed between the groups (14). As
outlined in the original trial (14), 16.6% (n 5 427 patients)
developed AF and would have provided an opportunity for
the influence of medication on the outcome in the current
trial. As a history of prior AF is known to predict further
episodes (annual risk of 9.6% in this trial), a large percentage
of these patients would have developed their index arrhyth-
mia on medications. As such, it is likely that the influence of
medication in the current trial was small at best.
Finally, LV function was objectively determined by echo-
cardiography or LV angiography in less than half of pa-
tients. In the remainder, investigators made presumptive
assessments and determined LV function as “normal” or
“abnormal.” While this determination is less quantitative, it
remains clinically relevant and easily applicable.
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